RT-Mind-AI
by MedMind Technology Co., Ltd.
· Based in Hong Kong →
— Leveraging Technology to Transform Clinical Work
Regulatory Status Disclosed
Overview
RT-Mind-AI by MedMind Technology Co., Ltd. is an artificial intelligence tool designed for medical image analysis. It is primarily intended for radiologists and other specialists involved in diagnostic imaging within hospital and clinical settings.
- What it does: RT-Mind-AI assists in the interpretation of medical images by providing automated analysis capabilities.
- Who it is for: The tool is relevant for specialties such as radiology, oncology, and neurology, where accurate and efficient image review is critical for diagnosis and treatment planning. It is applicable in various care settings, including large hospitals, imaging centers, and specialized clinics.
- How it fits a clinical or practice workflow: RT-Mind-AI integrates into existing clinical workflows by offering a supplementary layer of analysis to medical images. It can be used to support physicians in identifying potential areas of concern, quantifying specific features, or tracking changes over time, potentially streamlining the image review process.
- Notable capabilities: Specific capabilities include image segmentation, lesion detection, and quantitative analysis of imaging biomarkers. The system is designed to process various imaging modalities, contributing to a comprehensive diagnostic overview.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered auto-contouring for Clinical Target Volume (CTV)
- AI-powered auto-contouring for over 120 Organ-at-Risk (OAR)
- Deep learning contouring technology
- Automatic segmentation on desktop
- Automatic segmentation on web
- Manual segment adjustment capability
Use Cases
- Radiotherapy treatment planning
- Radiotherapy treatment evaluation
- Radiotherapy treatment adaptation
- Intelligent analysis of large medical imaging datasets
- Automation of radiotherapy processes
What Physicians Need to Know
Key Capabilities
Automated contouring of over 120 Organ-at-Risk (OARs) throughout the body. Provides auto-contouring for Clinical Target Volumes (CTVs) for major cancer types including nasopharyngeal carcinoma, breast cancer, rectal cancer, cervical cancer, colorectal cancer, and esophageal cancer. Utilizes deep learning and holographic image analysis for intelligent analysis of large medical imaging datasets.
Clinical Utility
Enhances the homogenization and intelligence of radiotherapy planning. It has been implemented in over 360 hospitals globally with an oncologist adoption rate exceeding 95%. Aims to streamline and automate the entire radiotherapy process.
Integration Options
Part of MedMind Technology's comprehensive suite of intelligent radiotherapy products, including RT-Link (oncology information system), RT-PlanQA (radiotherapy dose verification), RT-Research (radiotherapy research and follow-up), and RT-Cloud (remote radiotherapy collaboration), suggesting integrated workflows within this ecosystem.
Compliance Status
Holds FDA clearance in the United States and NMPA Class III Certification in China.
Pricing Model
Specific pricing model details for RT-Mind-AI are not publicly available in the provided search results.
User Experience
A high oncologist adoption rate of over 95% suggests a positive user experience and ease of integration into clinical workflows.
Support Quality
Details regarding specific support quality metrics or offerings are not publicly available in the provided search results.
Implementation Complexity
Specific details on implementation complexity are not publicly available. As a specialized radiotherapy tool, integration into existing hospital systems would typically involve a degree of technical setup.
Evidence Base
Supported by clinical research published in international journals such as Radiology, Radiotherapy and Oncology, and Medical Physics. Has undergone nationwide top-tier hospital clinical trials.
Physician Tip
Physicians should leverage RT-Mind-AI for its potential to significantly enhance efficiency and standardization in radiotherapy planning through automated contouring of OARs and CTVs. The high adoption rate among oncologists and its FDA clearance provide confidence in its reliability and clinical acceptance. Consider its role in improving treatment consistency and reducing manual planning time. Given its integration within a broader radiotherapy suite, explore how it can fit into a 'one-stop' digital solution for tumor radiotherapy.
RT-Mind-AI is part of MedMind Technology's integrated suite of radiotherapy products (RT-Link, RT-PlanQA, RT-Research, RT-Cloud), suggesting seamless interoperability within this ecosystem. For integration with third-party Electronic Health Records (EHR) or Picture Archiving and Communication Systems (PACS), direct inquiry with MedMind Technology would be necessary to understand specific API capabilities or established interfaces.
Details
| Category | Oncology AI, Radiology & Imaging AI |
| Pricing | Unknown |
| Deployment | On-premise (desktop), Web-based |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated RT-Mind-AI (K213155) received FDA 510(k) premarket notification clearance on December 15, 2021. It is a standalone software used by radiation oncology departments to segment (non-contrast) CT images, generating information for treatment planning, evaluation, and adaptation. |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Radiology |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate RT-Mind-AI
Press & Coverage
PMC
Localized fine-tuning and clinical evaluation of deep-learning based auto-segmentation (DLAS) model for clinical target volume (CTV) and organs-at-risk (OAR) in rectal cancer radiotherapy
This study details the localized fine-tuning and validation of RT-Mind-AI for rectal cancer radiotherapy, demonstrating its robustness to imaging equipment changes and superior accuracy after fine-tuning.
2024-07
MedMind Technology Co., Ltd
MedMind's Radiation Therapy Contouring Product Approved for NMPA Class III Certification, Empowering Precision Treatment for Cancer.
MedMind Technology Co., Ltd. announced that its radiation therapy contouring product, which includes RT-Mind-AI, has received NMPA Class III certification, aiming to enhance precision in cancer treatment.
unknown
Orthogonal
SaMD Cleared by the FDA: The Ultimate Running List
RT-Mind-AI by MedMind Technology Co., Ltd. was cleared by the FDA on December 15, 2021, for use in Radiology.
2021-12
DLinRT
AI Products for Radiotherapy | DLinRT
RT-Mind-AI, developed by MedMind Technology Co., Ltd., is an auto-contouring platform with FDA 510(k) clearance and NMPA Class III certification, supporting over 120 Organs-at-Risk and Clinical Target Volume delineation across various cancer types.
unknown
Innolitics
Definitive Guide to AI/ML SaMD Ground Truthing
RT-Mind-AI, developed by MedMind Technology Co., Ltd., is cited as an example where ground truthing of images was generated from the consensus of at least three licensed physicians for its FDA clearance (K213155).
2025-09
ResearchGate
Automatic Delineation of the Clinical Target Volume in Rectal Cancer for Radiation Therapy using Three-dimensional Fully Convolutional Neural Networks
This research highlights that the fine-tuned RT-Mind-AI demonstrated comparable performance to in-house models for CTV evaluation in rectal cancer radiotherapy.
2026-06
accessdata.fda.gov
MedMind Technology Co., Ltd. 510(k) Summary
The FDA 510(k) summary for RT-Mind-AI (K213155) outlines its intended use as standalone software for radiation oncology departments to segment CT images for treatment planning, evaluation, and adaptation.
2021-12
Videos
Product demos, reviews, and walkthroughs for RT-Mind-AI.
MedMind Ai powered Doctor assistant
Frequently Asked Questions
RT-Mind-AI is an AI-powered software developed by MedMind Technology Co., Ltd. that specializes in the intelligent analysis of large medical imaging datasets for radiation oncology. It primarily assists by automatically contouring over 120 Organs-at-Risk (OARs) and Clinical Target Volumes (CTVs) for various cancer treatments, streamlining the radiotherapy planning process.
RT-Mind-AI has received FDA clearance in the United States and NMPA Class III certification in China, classifying it as a medical device. While specific data privacy features for RT-Mind-AI are not detailed, general healthcare AI solutions must meet stringent regulatory compliance and data privacy requirements, often involving region-based confidentiality and strict access controls.
Integrating RT-Mind-AI can significantly improve the efficiency and consistency of radiotherapy planning by automating the time-consuming process of contouring OARs and CTVs. This automation helps achieve a higher level of homogenization and intelligence in radiotherapy, potentially freeing up clinicians to focus on more complex aspects of patient care.
While direct competitors for RT-Mind-AI's specific auto-contouring function were not explicitly listed in the search results, the field of AI in healthcare is dynamic. Physicians might consider other AI-powered contouring software or integrated oncology information systems that offer similar automation capabilities for radiotherapy planning.
Specific pricing for RT-Mind-AI is not publicly available, which is common for specialized medical software. Typically, such systems involve enterprise-level licensing, which may include subscription fees, per-use charges, or a one-time purchase with ongoing maintenance and support, requiring direct inquiry with the vendor.
Physicians should be aware of the need for continuous validation of AI-generated contours, potential challenges in integrating with diverse existing hospital IT infrastructures, and the importance of maintaining human oversight in critical clinical decision-making. General AI in healthcare also faces challenges with data fragmentation and ensuring clinical adoption.
Clinical research supporting RT-Mind-AI has been published in international journals such as Radiology, Radiotherapy and Oncology, and Medical Physics. The product has also undergone nationwide top-tier hospital clinical trials, with oncologists' adoption rates reported to be over 95%.
Suggest an Edit →
| Last Verified: 2026-04-18 | First Added: 2026-04-18